October 21, 2018

CEL-SCI REPORTS RECENT DATA REVIEW BY THE INDEPENDENT DATA MONITORING COMMITTEE FOR ITS PIVOTAL PHASE 3 HEAD AND NECK CANCER STUDY

CEL-SCI REPORTS RECENT DATA REVIEW BY THE INDEPENDENT DATA MONITORING COMMITTEE FOR ITS PIVOTAL PHASE 3 HEAD AND NECK CANCER STUDY Vienna, VA, August 15, 2018 — […]
October 21, 2018

CEL-SCI ANNOUNCES THAT THE NYSE AMERICAN APPROVES PLAN

CEL-SCI ANNOUNCES THAT THE NYSE AMERICAN APPROVES PLAN Vienna, VA, August 17, 2018 — CEL-SCI Corporation (NYSE American: CVM)announces that the NYSE American (the “Exchange”) has accepted the […]
October 21, 2018

CEL-SCI CORPORATION RELEASES LETTER TO SHAREHOLDERS

Vienna, VA, August 21, 2018 — The following letter was sent by CEL-SCI Corporation (NYSE American: CVM) to its shareholders for the upcoming annual meeting: Dear CEL-SCI […]
October 21, 2018

NIH SELECTS CEL-SCI’s LEAPS RHEUMATOID ARTHRITIS VACCINE FOR COMMERCIALIZATION ACCELERATOR PROGRAM

Vienna, VA, September 5, 2018 — CEL-SCI Corporation (NYSE American: CVM) announced today that the National Institutes of Health (NIH) selected CEL-SCI and its LEAPS* rheumatoid arthritis vaccine […]
October 21, 2018

CEL-SCI RECEIVES $5.4 MILLION FROM WARRANT EXERCISES

CEL-SCI RECEIVES $5.4 MILLION FROM WARRANT EXERCISES Vienna, VA, September 14, 2018 — CEL-SCI Corporation (NYSE American: CVM) announced today it has received $5,435,367 through the exercise of […]
October 21, 2018

CEL-SCI ANNOUNCES WARRANTS TO EXPIRE ON OCTOBER 11, 2018

CEL-SCI ANNOUNCES WARRANTS TO EXPIRE ON OCTOBER 11, 2018 Vienna, VA, September 28, 2018 — CEL-SCI Corporation (NYSE American: CVM) is advising the holders of its publicly traded […]
Font Resize